R-GEMOX方案治疗复发难治B细胞性非霍奇金淋巴瘤的疗效

摘要

Objective:To investigate the efficacy and toxicities of R-GEMOX regimen(rituximab,gemcitabine, oxaliplat)in the treatment of relapsed/refractor B-cell non-Hodgkin＇s lymphoma(NHL).Methods:Twenty patients with relapsed or refractor B-cell NHL after medication of traditional chemotherapy accepted R-GEMOX regimen, the efficacy toxicities was evaluated after at least 4 cycles of chemotherapy,the toxicities was evaluated after at least 1 cycles of chemotherapy.Results:Of the 20 cases,7 patients were in complete remission and 8 in partial remission,re-sulting in an overall remission rate of 75%(15/20).5 patients symptom disappeared,and 1 in 7 cases was alleviated of type B symptoms.The toxicity was mild.Conclusion:R-GEMOX regimen was effect for recurrent or refractory B-cell NHL,and the toxicities can be tolerated.This protocol was worthy to warranted as salvage for relapsed or refrac-tory B-cell NHL.%目的:观察R-GEMOX方案(利妥昔单抗联合吉西他滨、奥沙利铂)挽救性治疗复发、难治B细胞性非霍奇金淋巴瘤(non-Hodgkin＇s lymphoma,NHL)的近期疗效和毒副反应.方法:回顾性分析20例经正规标准方案治疗复发或难治的B细胞性NHL患者,采用R-GEMOX方案(利妥昔单抗375 mg/m2,第0天;吉西他滨1 000 mg/m2,静脉滴注,第1、8天;奥沙利铂130 mg/m2,静脉滴注,第1天),21～28 d为一个周期,每化疗4个周期后评价疗效,每1个周期化疗后评价毒副反应.结果:20例患者中,完全缓解(complete remission, CR)7例,部分缓解(partial remission,PR)8例,总有效率(CR+PR)为75%.7例具有B类症状的患者,5例症状消失,1例明显改善.毒副反应可耐受.结论:R-GEMOX方案对复发难治B细胞性NHL近期疗效较好,毒副反应小,是一个值得进一步验证的补救性化疗方案.